A Double-blind, Parallel-group, Comparative Study in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome

Trial Profile

A Double-blind, Parallel-group, Comparative Study in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2015

At a glance

  • Drugs Ramosetron (Primary)
  • Indications Irritable bowel syndrome
  • Focus Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 06 Nov 2015 Primary endpoint has been met. (Monthly responder rate of stool form normalization at final point), according to an article published in the Gastroenterology
    • 06 Nov 2015 Primary endpoint has been met. (Monthly responder rate of global assessment of relief of overall IBS symptoms at final point), according to an article published in the Gastroenterology
    • 06 Nov 2015 Results published in the Gastroenterology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top